vs
Side-by-side financial comparison of Cherry Hill Mortgage Investment Corp (CHMI) and FENNEC PHARMACEUTICALS INC. (FENC). Click either name above to swap in a different company.
FENNEC PHARMACEUTICALS INC. is the larger business by last-quarter revenue ($13.8M vs $11.8M, roughly 1.2× Cherry Hill Mortgage Investment Corp). On growth, FENNEC PHARMACEUTICALS INC. posted the faster year-over-year revenue change (73.8% vs -37.2%). Over the past eight quarters, Cherry Hill Mortgage Investment Corp's revenue compounded faster (-15.2% CAGR vs -26.3%).
Cherry Hill Mortgage Investment Corp is a U.S.-headquartered real estate finance firm focused on acquiring, investing in and managing residential mortgage-related assets. Its core holdings include agency mortgage-backed securities, residential loans and mortgage servicing rights, operating primarily in the U.S. domestic housing finance market.
Fennec Pharmaceuticals Inc. is a biopharmaceutical firm focused on developing and commercializing therapies to reduce treatment-related side effects in pediatric cancer patients. Its lead product targets chemotherapy-induced ototoxicity, with core North American markets serving oncology providers and vulnerable pediatric patient groups.
CHMI vs FENC — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $11.8M | $13.8M |
| Net Profit | — | $-4.8M |
| Gross Margin | 78.9% | — |
| Operating Margin | 72.1% | -18.5% |
| Net Margin | — | -34.7% |
| Revenue YoY | -37.2% | 73.8% |
| Net Profit YoY | — | -141.1% |
| EPS (diluted) | $0.18 | $-0.17 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $11.8M | $13.8M | ||
| Q3 25 | $8.6M | $12.5M | ||
| Q2 25 | $6.0M | $9.7M | ||
| Q1 25 | $-3.0M | $8.8M | ||
| Q4 24 | $18.7M | $7.9M | ||
| Q3 24 | $-7.1M | $7.0M | ||
| Q2 24 | $6.6M | $7.3M | ||
| Q1 24 | $16.3M | $25.4M |
| Q4 25 | — | $-4.8M | ||
| Q3 25 | $4.5M | $-638.0K | ||
| Q2 25 | $1.6M | $-3.2M | ||
| Q1 25 | $-7.0M | $-1.2M | ||
| Q4 24 | — | $-2.0M | ||
| Q3 24 | $-12.4M | $-5.7M | ||
| Q2 24 | $784.0K | $-5.6M | ||
| Q1 24 | $12.1M | $12.8M |
| Q4 25 | 78.9% | — | ||
| Q3 25 | 73.2% | — | ||
| Q2 25 | 67.7% | — | ||
| Q1 25 | 183.4% | — | ||
| Q4 24 | 83.3% | — | ||
| Q3 24 | 145.3% | — | ||
| Q2 24 | 47.5% | — | ||
| Q1 24 | 83.9% | — |
| Q4 25 | 72.1% | -18.5% | ||
| Q3 25 | 56.0% | -1.5% | ||
| Q2 25 | 44.4% | -28.3% | ||
| Q1 25 | 223.6% | -9.2% | ||
| Q4 24 | 76.2% | -11.8% | ||
| Q3 24 | 171.8% | -74.6% | ||
| Q2 24 | 22.0% | -69.4% | ||
| Q1 24 | 78.0% | 54.2% |
| Q4 25 | — | -34.7% | ||
| Q3 25 | 52.7% | -5.1% | ||
| Q2 25 | 25.9% | -32.7% | ||
| Q1 25 | 229.2% | -13.3% | ||
| Q4 24 | — | -25.0% | ||
| Q3 24 | 175.8% | -82.2% | ||
| Q2 24 | 11.9% | -76.5% | ||
| Q1 24 | 73.7% | 50.6% |
| Q4 25 | $0.18 | $-0.17 | ||
| Q3 25 | $0.05 | $-0.02 | ||
| Q2 25 | $-0.03 | $-0.11 | ||
| Q1 25 | $-0.29 | $-0.04 | ||
| Q4 24 | $0.30 | $-0.02 | ||
| Q3 24 | $-0.49 | $-0.21 | ||
| Q2 24 | $-0.06 | $-0.20 | ||
| Q1 24 | $0.32 | $0.41 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $54.9M | $36.8M |
| Total DebtLower is stronger | $146.3M | — |
| Stockholders' EquityBook value | $236.0M | $35.5M |
| Total Assets | $1.5B | $70.6M |
| Debt / EquityLower = less leverage | 0.62× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $54.9M | $36.8M | ||
| Q3 25 | $55.4M | $21.9M | ||
| Q2 25 | $58.0M | $18.7M | ||
| Q1 25 | $47.3M | $22.7M | ||
| Q4 24 | $46.3M | $26.6M | ||
| Q3 24 | $50.2M | $40.3M | ||
| Q2 24 | $52.4M | $43.1M | ||
| Q1 24 | $47.5M | $51.2M |
| Q4 25 | $146.3M | — | ||
| Q3 25 | $148.0M | $19.4M | ||
| Q2 25 | $150.1M | $19.4M | ||
| Q1 25 | $150.1M | $19.4M | ||
| Q4 24 | $152.1M | $19.3M | ||
| Q3 24 | $151.8M | $32.1M | ||
| Q2 24 | $160.5M | $31.8M | ||
| Q1 24 | $167.5M | $31.3M |
| Q4 25 | $236.0M | $35.5M | ||
| Q3 25 | $233.1M | $-4.5M | ||
| Q2 25 | $229.9M | $-7.5M | ||
| Q1 25 | $226.6M | $-5.9M | ||
| Q4 24 | $230.3M | $-5.9M | ||
| Q3 24 | $236.7M | $-5.2M | ||
| Q2 24 | $234.5M | $-1.4M | ||
| Q1 24 | $247.0M | $3.0M |
| Q4 25 | $1.5B | $70.6M | ||
| Q3 25 | $1.5B | $49.3M | ||
| Q2 25 | $1.5B | $44.9M | ||
| Q1 25 | $1.4B | $46.4M | ||
| Q4 24 | $1.5B | $44.9M | ||
| Q3 24 | $1.6B | $58.9M | ||
| Q2 24 | $1.4B | $63.2M | ||
| Q1 24 | $1.4B | $69.2M |
| Q4 25 | 0.62× | — | ||
| Q3 25 | 0.63× | — | ||
| Q2 25 | 0.65× | — | ||
| Q1 25 | 0.66× | — | ||
| Q4 24 | 0.66× | — | ||
| Q3 24 | 0.64× | — | ||
| Q2 24 | 0.68× | — | ||
| Q1 24 | 0.68× | 10.40× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $19.1M | $-6.0M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $19.1M | $-6.0M | ||
| Q3 25 | $-2.4M | $1.5M | ||
| Q2 25 | $12.5M | $-3.7M | ||
| Q1 25 | $682.0K | $-4.3M | ||
| Q4 24 | $-4.7M | $-1.5M | ||
| Q3 24 | $4.4M | $-2.2M | ||
| Q2 24 | $4.1M | $-8.4M | ||
| Q1 24 | $-19.1M | $39.0M |
| Q4 25 | — | — | ||
| Q3 25 | -0.53× | — | ||
| Q2 25 | 7.98× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 5.18× | — | ||
| Q1 24 | -1.58× | 3.04× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
